Physician profile

Amanda Jane Stephens

Gynecologic Oncology · Tallahassee, FL

NPI 1730446006

$1,334.31

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$52.92

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $262.81 2019
Tesaro, INC. $228.02 2019
Astrazeneca Pharmaceuticals LP $221.53 2020-2022
Biom'Up France Sas $219.02 2020-2021
Conmed Corporation $152.34 2019
Clovis Oncology, INC. $113.85 2019
Myriad Genetic Laboratories, INC. $69.93 2022
Eisai INC. $36.00 2023
Astellas Pharma US INC $16.92 2024 Veozah
Glaxosmithkline, LLC. $13.89 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amanda Jane Stephens

$1,334.31

in general payments reported 2019-2025

Years
2019-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/215069/amanda-jane-stephens

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.